Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial

Press brief by Meletios Dimopoulos, MD of the University of Athens, Athens, Greece, at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.

Share this video  
Similar topics